Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns

被引:41
|
作者
Emoto, C. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 4702393, Japan
关键词
CYP3A4; CYP3A5; alpha-naphthoflavone; interaction;
D O I
10.1080/00498250500489968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity. To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates. Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6 beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively. In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4. An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alpha NF) and CYP3A substrates were different for the two CYP3A enzymes. alpha NF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4. alpha NF at less than 32 mu M inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4. These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions.
引用
收藏
页码:219 / 233
页数:15
相关论文
共 50 条
  • [21] APPLICATION OF CYP3A4 IN VITRO DATA TO PREDICT CLINICAL DRUG-DRUG INTERACTIONS; PREDICTIONS OF COMPOUNDS AS OBJECTS OF INTERACTION
    Youdim, Kuresh A.
    Dickins, Maurice
    Phipps, Alex
    Darekar, Amanda
    Hyland, Ruth
    Fahmi, Odette
    Hurst, Susan
    Cook, Jack
    Plowchalk, David
    Guo, Feng
    Obach, Scott
    DRUG METABOLISM REVIEWS, 2008, 40 : 84 - 85
  • [22] Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on Modeling CYP3A-Mediated Drug-Drug Interactions
    Shirasaka, Yoshiyuki
    Chang, Shu-Ying
    Grubb, Mary F.
    Peng, Chi-Chi
    Thummel, Kenneth E.
    Isoherranen, Nina
    Rodrigues, A. David
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (08) : 1566 - 1574
  • [23] CYP3A mediated drug-drug interactions: Contribution of CYP 3A4 and CYP 3A5
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1057 - 1057
  • [24] IMPACT OF CYP3A5 EXPRESSION ON THE INHIBITION OF CYP3A-CATALYZED DRUG METABOLISM: CONSIDERATIONS FOR MODELING CYP3A-MEDIATED DRUG-DRUG INTERACTIONS
    Shirasaka, Yoshiyuki
    Peng, Chi-Chi
    Chang, Shu-Ying
    Grubb, Mary F.
    Johnson, Stephen R.
    Rodrigues, A. David
    Thummel, Kenneth E.
    Isoherranen, Nina
    DRUG METABOLISM REVIEWS, 2012, 44 : 83 - 84
  • [25] Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism
    Ya-nan Liu
    Jie Chen
    Jing Wang
    Qingqing Li
    Guo-xin Hu
    Jian-ping Cai
    Guanyang Lin
    Ren-ai Xu
    Archives of Toxicology, 2023, 97 : 2133 - 2142
  • [26] Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism
    Liu, Ya-nan
    Chen, Jie
    Wang, Jing
    Li, Qingqing
    Hu, Guo-xin
    Cai, Jian-ping
    Lin, Guanyang
    Xu, Ren-ai
    ARCHIVES OF TOXICOLOGY, 2023, 97 (08) : 2133 - 2142
  • [27] Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study
    Callegari, Ernesto
    Tse, Susanna
    Doran, Angela C.
    Goosen, Theunis C.
    Shaik, Naveed
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (01): : 80 - 93
  • [28] Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
    Denisov, Ilia G.
    Grinkova, Yelena V.
    McLean, Mark A.
    Camp, Tyler
    Sligar, Stephen G.
    BIOMOLECULES, 2022, 12 (06)
  • [29] Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin
    Dutreix, Catherine
    Lorenzo, Sebastien
    Wang, Yanfeng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) : 915 - 920
  • [30] Quantitative prediction of CYP3A4 drug-drug interactions: Extending the strategy
    Galetin, A
    Hallifax, D
    Ito, K
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 62 - 62